Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01485900
Recruitment Status : Completed
First Posted : December 6, 2011
Last Update Posted : August 23, 2012
Information provided by (Responsible Party):

November 24, 2011
December 6, 2011
August 23, 2012
November 2011
August 2012   (Final data collection date for primary outcome measure)
Number of patients reporting Adverse Events (AEs) [ Time Frame: 8 weeks ]
Same as current
Complete list of historical versions of study NCT01485900 on Archive Site
  • Clinical safety laboratory measurement including hematology and biochemistry [ Time Frame: 8 weeks ]
  • urine and blood renal function markers [ Time Frame: 8 weeks ]
  • ECG, vital signs measurements (Heart rate and systolic and diastolic blood pressure) [ Time Frame: 8 weeks ]
  • AcSDKP (tetrapeptide of the composition N-Acetyl-Ser-Asp-Lys-Pro) [ Time Frame: 8 weeks ]
  • AUC [ Time Frame: 8 weeks ]
  • Cmax [ Time Frame: 8 weeks ]
  • t1/2z [ Time Frame: 8 weeks ]
  • 24-hr ambulatory blood pressure [ Time Frame: Day-1, Day 14 and Day 19 ]
Same as current
Not Provided
Not Provided
Repeated Dosing Study to Assess Safety and Tolerability in CKD-3 Patients on Stable ACE-I Treatment
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Hemodynamics of Ascending Repeated Oral Doses of SAR407899A in Patients With Moderate Chronic Kidney Disease on Stable Angiotensin Converting Enzyme-inhibitor (ACE-I) Treatment

Primary Objective:

  • To assess the tolerability and safety of repeated oral ascending doses of SAR407899A in patients with moderate chronic kidney disease (CKD) on stable angiotensin converting enzyme-inhibitor (ACE-I)

Secondary Objectives:

  • To assess in patients with moderate CKD the effect of concomitant multiple dose of SAR407899A and ACE-Is on office and 24-hr ambulatory blood pressure and heart rate
  • The effect of repeated multiple doses of SAR407899A on the pharmacodynamic response to ACE-Is (AcSDKP)
  • The pharmacokinetic profile of repeated oral administration of SAR407899A during co-administration of ACE-Is
The total duration for this study will be around 8 weeks.
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Chronic Kidney Disease
Drug: SAR407899A

Pharmaceutical form:capsule

Route of administration: oral

  • Experimental: Cohort 1
    Dose 1: 20 days 3-step uptitration with doses A, B, and C of SAR407899 vs. placebo
    Intervention: Drug: SAR407899A
  • Experimental: Cohort 2
    Dose 2: 20 days 3-step uptitration with doses B, C and D of SAR407899 vs. placebo
    Intervention: Drug: SAR407899A
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2012
August 2012   (Final data collection date for primary outcome measure)

Inclusion criteria:

  • Male and female patients aged between 18 and 79
  • Patients with chronic kidney disease (CKD-3)
  • Patients should be on stable ACE-I treatment (same type and regimen) for at least 2 months prior to screening
  • Body weight between 50.0 kg and 115.0 kg inclusive if male, between 40.0 kg and 100 kg inclusive if female
  • If female, patients must be permanently sterilized for more than 3 months or postmenopausal
  • Having given written informed consent prior to the study.

Exclusion criteria:

  • Women of child bearing potential.
  • Uncontrolled clinically relevant cardiovascular, pulmonary, gastro-intestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female) or infectious disease, or signs of acute illness
  • Active hepatitis, hepatic insufficiency
  • Acute renal failure
  • Patients requiring dialysis during the study
  • Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician.
  • Any history of orthostatic dysregulation (including but not limited to neurocardiogenic syncope, postural orthostatic tachycardia syndrome)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sexes Eligible for Study: All
18 Years to 79 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Moldova, Republic of,   Romania
2011-003793-83 ( EudraCT Number )
U1111-1123-5699 ( Other Identifier: UTN )
Not Provided
Not Provided
Not Provided
Study Director: Clinical Sciences & Operations Sanofi
August 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP